Skip to Main Content

INFORMATION FOR

Michael Sernyak Jr, MD

Professor of Psychiatry; Deputy Chair for Clinical Affairs and Program Development, Department of Psychiatry; CEO, Connecticut Mental Health Center

Contact Information

Michael Sernyak Jr, MD

Mailing Address

  • Psychiatry

    300 George St

    New Haven, CT 06511-

    United States

Coauthors

Selected Publications

  • Administrative Best Practices in Public PsychiatryBarkil-Oteo A, Bailey M, Cole R, Delphin-Rittmon M, Devine S, Jacobs S, Steiner J, Trevisan L, Sernyak M. Administrative Best Practices in Public Psychiatry 2016, 261-272. DOI: 10.1093/med/9780190214678.003.0018.
  • Integrated Health CareAnnamalai A, Tek C, Sernyak M, Cole R, Steiner J. Integrated Health Care 2016, 63-80. DOI: 10.1093/med/9780190214678.003.0005.
  • Introduction and SignificanceJacobs S, Ball S, Davidson L, Díaz E, DeSanto Iennaco J, McMahon T, Rohrbaugh R, Steiner J, Styron T, Sernyak M, Zonana H. Introduction and Significance 2016, 1-12. DOI: 10.1093/med/9780190214678.003.0001.
  • Conclusion and Future ChallengesJacobs S, Ball S, Davidson L, Díaz E, DeSanto Iennaco J, McMahon T, Rohrbaugh R, Steiner J, Styron T, Sernyak M, Zonana H. Conclusion and Future Challenges 2016, 273-286. DOI: 10.1093/med/9780190214678.003.0019.
  • Generic Fluoxetine and Choice of Antidepressant MedicationSernyak M, Rosenheck R. Generic Fluoxetine and Choice of Antidepressant Medication Psychiatric Services 2007, 58: 128-130. DOI: 10.1176/ps.2007.58.1.128.
  • Predictors of Antipsychotic Medication ChangeSernyak M, Leslie D, Rosenheck R. Predictors of Antipsychotic Medication Change The Journal Of Behavioral Health Services & Research 2005, 32: 85???94. DOI: 10.1097/00075484-200501000-00007.
  • Clozapine in prevention of suicide in patients with schizophrenia: profile reportSernyak M. Clozapine in prevention of suicide in patients with schizophrenia: profile report Drugs & Therapy Perspectives 2003, 19: 5-6. DOI: 10.2165/00042310-200319080-00002.
  • Clozapine and Prevention of Suicide in SchizophreniaSernyak M. Clozapine and Prevention of Suicide in Schizophrenia CNS Drugs 2003, 17: 281-281. DOI: 10.2165/00023210-200317040-00006.
  • Dr. Sernyak and Colleagues ReplySERNYAK M, LESLIE D, ALARCON R, LOSONCZY M, ROSENHECK R. Dr. Sernyak and Colleagues Reply American Journal Of Psychiatry 2003, 160: 389-389. DOI: 10.1176/appi.ajp.160.2.389.
  • Dr. Sernyak and Colleagues ReplySERNYAK M, DESAI R, ROSENHECK R. Dr. Sernyak and Colleagues Reply American Journal Of Psychiatry 2002, 159: 324-324. DOI: 10.1176/appi.ajp.159.2.324.
  • 435. Dose-response of THC effects in schizophrenics and healthy controlsD'Souza D, Belger A, Abi-Saab W, Adams S, Gil R, Larvey K, Cassello K, Sernyak M, Krystal J. 435. Dose-response of THC effects in schizophrenics and healthy controls Biological Psychiatry 1998, 43: s130-s131. DOI: 10.1016/s0006-3223(98)90883-6.
  • 496 Preliminary assessment of cortical gaba levels in schizophrenics using magnetic resonance spectroscopyBehar K, Rothman D, D’Souza D, Gil R, Petroff O, Abi-Saab D, Zuzarte E, Hooten M, Petrakis I, Sernyak M, White J, Webb E, Charnay D, Krystal J. 496 Preliminary assessment of cortical gaba levels in schizophrenics using magnetic resonance spectroscopy Schizophrenia Research 1997, 24: 175-176. DOI: 10.1016/s0920-9964(97)82504-2.
  • 584 Quantitative measurement of antipsychotic medication compliance in chronic schizophrenic patientsDiaz E, Levine H, Sullivan M, Sernyak M, Hawkins K, Cramer J, Woods S. 584 Quantitative measurement of antipsychotic medication compliance in chronic schizophrenic patients Schizophrenia Research 1997, 24: 206. DOI: 10.1016/s0920-9964(97)82592-3.
  • Spect imaging of the benzodiazepine receptor in schizophrenics and healthy subjectsAbi-Dargham A, Krystal J, Laruelle M, D'Souza D, Zoghbi S, Brenner L, Gil R, Sernyak M, Baldwin R, Zubal G, Hoffer P, Charney D, Innis R. Spect imaging of the benzodiazepine receptor in schizophrenics and healthy subjects Schizophrenia Research 1995, 15: 75. DOI: 10.1016/0920-9964(95)95236-3.